176 related articles for article (PubMed ID: 38378820)
1. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 Feb; ():. PubMed ID: 38378820
[TBL] [Abstract][Full Text] [Related]
2. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
3. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Perils and Problems in Bispecific T-Cell Engager Antibodies.
Khushboo B; Kumar JR
Curr Drug Saf; 2024 Feb; ():. PubMed ID: 38424423
[TBL] [Abstract][Full Text] [Related]
6. Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice.
Godbersen-Palmer C; Coupet TA; Grada Z; Zhang SC; Sentman CL
J Immunol; 2020 Jun; 204(11):2973-2983. PubMed ID: 32295875
[TBL] [Abstract][Full Text] [Related]
7. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
8. An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.
Wang N; Patel H; Schneider IC; Kai X; Varshney AK; Zhou L
Antib Ther; 2021 Apr; 4(2):90-100. PubMed ID: 34169228
[TBL] [Abstract][Full Text] [Related]
9. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells.
Liu L; Chen J; Bae J; Li H; Sun Z; Moore C; Hsu E; Han C; Qiao J; Fu YX
Nat Biomed Eng; 2021 Nov; 5(11):1261-1273. PubMed ID: 34725504
[TBL] [Abstract][Full Text] [Related]
10. T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
Quitt O; Luo S; Meyer M; Xie Z; Golsaz-Shirazi F; Loffredo-Verde E; Festag J; Bockmann JH; Zhao L; Stadler D; Chou WM; Tedjokusumo R; Wettengel JM; Ko C; Noeßner E; Bulbuc N; Shokri F; Lüttgau S; Heikenwälder M; Bohne F; Moldenhauer G; Momburg F; Protzer U
J Hepatol; 2021 Nov; 75(5):1058-1071. PubMed ID: 34171437
[TBL] [Abstract][Full Text] [Related]
11. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
[TBL] [Abstract][Full Text] [Related]
12. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys.
Harper T; Sharma A; Kaliyaperumal S; Fajardo F; Hsu K; Liu L; Davies R; Wei YL; Zhan J; Estrada J; Kvesic M; Nahrwold L; Deisting W; Panzer M; Cooke K; Lebrec H; Nolan-Stevaux O
Toxicol Sci; 2022 Aug; 189(1):32-50. PubMed ID: 35583313
[TBL] [Abstract][Full Text] [Related]
15. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
16. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
[TBL] [Abstract][Full Text] [Related]
17. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
18. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
19. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
20. TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome.
Carrara SC; Harwardt J; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2022; 13():1051875. PubMed ID: 36439165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
